Editing Oncolytics Biotech Inc.
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 81: | Line 81: | ||
After the cell has burst all of the daughter Pelareorep cells are released to continue the process in surrounding cancer cells with the same glycans, until all cancerous cells have been defeated. | After the cell has burst all of the daughter Pelareorep cells are released to continue the process in surrounding cancer cells with the same glycans, until all cancerous cells have been defeated. | ||
Pelareorep has been clinically tested in partnership with Canadian Cancer Trials Group for pancreatic, breast, head, neck, prostate, lung, colorectal, bladder and ovarian cancers. Breast and pancreatic cancer tests have shown statistically significant results and have moved to Phase III clinical trials, on track for licence enabling studies. The clinical tests have also shown '''low death rates and less adverse side effects''' in comparison to chemotherapy. Side effects are: chills, fever, headache, cough, myalgia, runny nose, sore throat, fatigue, lymphopenia or neutropenia all for less than 6 hours. | Pelareorep has been clinically tested in partnership with Canadian Cancer Trials Group for pancreatic, breast, head, neck, prostate, lung, colorectal, bladder and ovarian cancers. Breast and pancreatic cancer tests have shown statistically significant results and have moved to Phase III clinical trials, on track for licence enabling studies. The clinical tests have also shown '''low death rates and less adverse side effects''' in comparison to chemotherapy. Side effects are: chills, fever, headache, cough, myalgia, runny nose, sore throat, fatigue, lymphopenia or neutropenia all for less than 6 hours. | ||
Line 92: | Line 90: | ||
* Selectively destroys tumour cells, not normal, healthy cells | * Selectively destroys tumour cells, not normal, healthy cells | ||
* It has a predictive biomarker- peripheral T-cell clonality | * It has a predictive biomarker- peripheral T-cell clonality | ||
Pelareorep is manufactured at a commercial scale under a commercial supply agreement with '''MilliporeSigma''' (formerly Sigma-Aldrich)<ref>https://www.oncolyticsbiotech.com/technology/manufacturing</ref>. | Pelareorep is manufactured at a commercial scale under a commercial supply agreement with '''MilliporeSigma''' (formerly Sigma-Aldrich)<ref>https://www.oncolyticsbiotech.com/technology/manufacturing</ref>. At the moment, Pelareorep is mainly supplied to Canada and the US, however the company is looking to expand to other countries with 17 pending patent applications. | ||
Currently the price of Pelareorep is unknown as it isn't officially a marketed drug, but it is likely to be equivalent to the price of Pfizer's Paclitaxel at '''$18 for a supply of 5 millilitres.''' | Currently the price of Pelareorep is unknown as it isn't officially a marketed drug, but it is likely to be equivalent to the price of Pfizer's Paclitaxel at '''$18 for a supply of 5 millilitres.''' |